Compare VanEck Junior Gold Miners (GDXJ) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Johnson & Johnson — how do they compare? VanEck Junior Gold Miners trades at $118.68, while Johnson & Johnson trades at $260.9 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while VanEck Junior Gold Miners pays none, and Johnson & Johnson is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals.
| GDXJ | JNJ | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $267.24 |
52-Week Low | $71.22 | $172.78 |
Market Cap | — | $626.09B |
Volume | — | 6,156,228 |
Enterprise Value | — | $654.37B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ (VanEck Junior Gold Miners ETF) trades at $119.44, up 0.56% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows mixed sentiment with institutional selling by Amundi reducing its stake by 50.5% in the latest quarter (Defense World, August 6, 2026). Recent underperformance versus peers and gold ETFs highlights challenges in the junior gold mining sector.
Outlook remains cautious due to high RSI levels suggesting overbought conditions and sector-specific headwinds. Investment opportunity hinges on gold price momentum, but risks include Federal Reserve policy uncertainty and competitive pressure from senior miners. Analyst sentiment is neutral with concerns about portfolio composition and small-cap exposure.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
